Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 27, 2010
- Accepted August 27, 2010
- First Published February 7, 2011.
Author Disclosures
- A. Vennegoor, MD,
- M.P. Wattjes, PhD,
- E.T.L. van Munster, PhD,
- R.L. Kriekaart, MD,
- B.W. van Oosten, PhD,
- F. Barkhof, PhD,
- J. Killestein, PhD and
- C.H. Polman, PhD
- A. Vennegoor, MD,
- M.P. Wattjes, PhD,
- E.T.L. van Munster, PhD,
- R.L. Kriekaart, MD,
- B.W. van Oosten, PhD,
- F. Barkhof, PhD,
- J. Killestein, PhD and
- C.H. Polman, PhD
- From the Departments of Neurology (A.V., B.W.v.O., J.K., C.H.P.) and Radiology (M.P.W., F.B.), MS Center Amsterdam, VU University Medical Center, Amsterdam; and Department of Neurology (E.T.L., R.L.), Jeroen Bosch Hospital, ‘s Hertogenbosch, the Netherlands.
- Address correspondence and reprint requests to Dr. A. Vennegoor, VU University Medical Center, Department of Neurology, PO Box 7057, 1007 MB Amsterdam, the Netherlands; a.vennegoor{at}vumc.nl
Article usage
Cited By...
Letters: Rapid online correspondence
- Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS
- Michael Y. Ko, Assistant Professor, 1653 Rush University Medical Ctr, W. Congress Parkway, Chicago, Illinois 60612michael_ko@rush.edu
- Dusan Stefoski, Roumen Balabanov
Submitted May 25, 2011 - Reply from the authors
- A. Vennegoor, MS Center Amsterdam, MS Center Amsterdam, the NetherlandsA.Vennegoor@vumc.nl
- M.P. Wattjes, E.T.L. van Munster, J. Killestein, and C.H.
Submitted May 25, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumabAlyssa A. Toorop, Zoë Y.G. van Lierop, Eva E.M. Strijbis et al.Neurology: Neuroimmunology & Neuroinflammation, October 13, 2020 -
Articles
Immune reconstitution inflammatory syndrome in natalizumab-associated PMLI.L. Tan, J.C. McArthur, D.B. Clifford et al.Neurology, August 10, 2011 -
Articles
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyP. Vermersch, L. Kappos, R. Gold et al.Neurology, May 16, 2011 -
Article
Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathyEvelyn Dubois, Christoph Ruschil, Felix Bischof et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2015